Search This Blog

Wednesday, May 6, 2026

UroGen revenue beats, reiterates 2026 JELMYTO and operating expense guidance

 UroGen Pharma Q1 2026 revenue rises 152% YoY to $51.0M, ZUSDURI up 109% QoQ to $29.2M above prior expectations, reiterates 2026 JELMYTO and operating expense guidance

https://finviz.com/quote?t=URGN&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.